Literature DB >> 26629123

Correlation between CYP4F2 gene rs2108622 polymorphism and susceptibility to ischemic stroke.

Chong Meng1, Juan Wang2, Wei-Ning Ge3, Shao-Can Tang4, Guang-Ming Xu5.   

Abstract

OBJECTIVE: To conduct a meta-analysis for the correlation between cytochrome P450 4F2 (CYP4F2) rs2108622 (V433M) gene polymorphism and ischemic stroke.
METHODS: We retrieved the case-control studies on the correlation between CYP4F2 V433M polymorphism and ischemic stroke included in domestic and international databases before January 2015 and selected the best genetic model, using RevMan 5.2 software for meta-analysis. According to the heterogeneity test results of selected literature, the effect model of consolidated data was selected, and the combined OR and 95% CI were calculated.
RESULTS: A total of six documents were included. Recessive model (VM + MM vs. VV) was selected as the best genetic model. The combined results showed that: compared with wild-type VV, there are significant association between ischemic stroke and CYP4F2 polymorphism (OR merge = 1.37, 95% CI: 1.21~1.54, P < 0.001).
CONCLUSION: CYP4F2 V433M may be the susceptibility gene for ischemic stroke.

Entities:  

Keywords:  Ischemic stroke; cytochrome P450 4F2; gene polymorphism; meta-analysis; susceptibility

Year:  2015        PMID: 26629123      PMCID: PMC4659012     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  14 in total

1.  CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.

Authors:  Yi Jin; Markus Zollinger; Hubert Borell; Alfred Zimmerlin; Christopher J Patten
Journal:  Drug Metab Dispos       Date:  2010-11-02       Impact factor: 3.922

2.  The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure.

Authors:  Cristiano Fava; Martina Montagnana; Peter Almgren; Lena Rosberg; Giuseppe Lippi; Bo Hedblad; Gunnar Engström; Göran Berglund; Pietro Minuz; Olle Melander
Journal:  Hypertension       Date:  2008-06-23       Impact factor: 10.190

3.  The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss.

Authors:  Natalie C Ward; Kevin D Croft; Ian B Puddey; Michael Phillips; Frank van Bockxmeer; Lawrence J Beilin; Anne E Barden
Journal:  J Hypertens       Date:  2014-07       Impact factor: 4.844

4.  CYP4F2 gene single nucleotide polymorphism is associated with ischemic stroke.

Authors:  H-Q Yan; Y Yuan; P Zhang; Z Huang; L Chang; Y-K Gui
Journal:  Genet Mol Res       Date:  2015-01-30

5.  Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.

Authors:  Ruijuan Liang; Chunling Wang; Hong Zhao; Jie Huang; Dayi Hu; Yihong Sun
Journal:  Thromb Res       Date:  2011-12-20       Impact factor: 3.944

6.  Efficacy of intravesical chondroitin sulphate in treatment of interstitial cystitis/bladder pain syndrome (IC/BPS): Individual patient data (IPD) meta-analytical approach.

Authors:  Ammarin Thakkinstian; J Curtis Nickel
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

7.  A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men.

Authors:  Zhenyan Fu; Tomohiro Nakayama; Naoyuki Sato; Yoichi Izumi; Yuji Kasamaki; Atsushi Shindo; Masakatsu Ohta; Masayoshi Soma; Noriko Aoi; Mikano Sato; Koichi Matsumoto; Yukio Ozawa; Yitong Ma
Journal:  Am J Hypertens       Date:  2008-09-11       Impact factor: 2.689

8.  A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure.

Authors:  Natalie C Ward; I-Jung Tsai; Anne Barden; Frank M van Bockxmeer; Ian B Puddey; Jonathan M Hodgson; Kevin D Croft
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.

Authors:  Wenfang Zhuang; Wei Wen; Binbin Xuan; Yanhong Chen; Yanan Cao; Zhixin Sun; Jun Ma
Journal:  Blood Coagul Fibrinolysis       Date:  2015-03       Impact factor: 1.276

Review 10.  Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Authors:  E Danese; M Montagnana; J A Johnson; A E Rettie; C F Zambon; S A Lubitz; G Suarez-Kurtz; L H Cavallari; L Zhao; M Huang; Y Nakamura; T Mushiroda; M K Kringen; P Borgiani; C Ciccacci; N T Au; T Langaee; V Siguret; M A Loriot; H Sagreiya; R B Altman; M H A Shahin; S A Scott; S I Khalifa; B Chowbay; I M Suriapranata; M Teichert; B H Stricker; M Taljaard; M R Botton; J E Zhang; M Pirmohamed; X Zhang; J F Carlquist; B D Horne; M T M Lee; V Pengo; G C Guidi; P Minuz; C Fava
Journal:  Clin Pharmacol Ther       Date:  2012-11-07       Impact factor: 6.875

View more
  2 in total

Review 1.  Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) rs1558139, rs2108622 polymorphisms and susceptibility to several cardiovascular and cerebrovascular diseases.

Authors:  Tao Zhang; Kuiying Yu; Xuhua Li
Journal:  BMC Cardiovasc Disord       Date:  2018-02-09       Impact factor: 2.298

2.  The correlation between CYP4F2 variants and chronic obstructive pulmonary disease risk in Hainan Han population.

Authors:  Yipeng Ding; Yixiu Yang; Quanni Li; Qiong Feng; Dongchuan Xu; Cibing Wu; Jie Zhao; Xiaoli Zhou; Huan Niu; Ping He; Jianfang Liu; Hongxia Yao
Journal:  Respir Res       Date:  2020-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.